'Malignant'Middle Cerebral Artery Territory Infarction
Arch Neurol 53:309-315, Macke,W.,et al, 1996
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Gray Matter Involvement in Multiple Sclerosis
Neurol 68:634-642, Pirko,I.,et al, 2007
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Early Clinical and Radiological Predictors of Fatal Brain Swelling in Ischemic Stroke
Stroke 30:287-292, Krieger,D.W.,et al, 1999
Ischemic Lesion Volumes in Acute Stroke by Diffusion-Weighted MRI Correlate with Clinical Outcome
Ann Neurol 42:164-170, Lovblad,K-O.,et al, 1997
Posttraumatic Headache
Semin Neurol 14:40-45, Packard,R.C., 1994
End-State Alzheimer's Disease:Glasgow Coma Scale and the Neurologic Examination
Arch Neurol 50:1309-1315, Benesch,C.G.,et al, 1993
Deteriorating Ischemic Stroke:Risk Factors and Prognosis
Neurol 40:1865-1869, Davalos,A.,et al, 1990
Management of Aneurysmal Subarachnoid Hemorrhage
Stroke 19:1300-1305, Biller,J.,et al, 1988